CATARAX eye drops are a medication designed to prevent the formation of cataracts in the eye. These drops contain azapentacene, a synthetic compound that inhibits the cross-linking of proteins in the lens of the eye, helping to maintain visual clarity and prevent further damage. Simply apply a drop in each eye and experience relief from cataract-related symptoms.
1 ml of the drug contains:
- Active ingredient – Sodium Azapentacene Polysulfonate (with 5% excess) 0.1500 mg (0.1575 mg),
- Excipients : boric acid, sodium tetraborate (borax), potassium chloride, thiomersal, methyl parahydroxybenzoate, propyl parahydroxybenzoate, 10% sodium hydroxide solution, purified water.
With topical application of azapentacene, systemic absorption is low.
Azapentacene is a p-benzoquinonic derivative, protects the sulfhydryl groups of the lens from oxidation, inhibits the formation of quinoid compounds and promotes the resorption of opaque lens proteins. Additionally activates proteolytic enzymes contained in the aqueous humor of the anterior chamber of the eye, thus facilitating the resorption of already formed opacities.
Available data on the use of Catarax have shown that systematic use prevents the development of senile cataracts and slows the degeneration of the lens in patients at risk, preventing or slowing down the development of cataracts.
Indications for use
– senile cataract
– traumatic cataract
– congenital cataract
– secondary cataract
Dosage and administration
For application to the eyes.
The recommended dose is 2 drops in the conjunctival sac of the affected eye(s) 3 to 5 times daily.
After instillation of the drug, it is recommended to press the nasolacrimal canal or carefully cover the eyelids. This reduces the systemic absorption of the drug and systemic adverse effects.
Use in persons with impaired liver and / or kidney function
There are no reliable data on the use of azapentacene in patients with impaired liver and / or kidney function, so the drug should be prescribed with caution.
Use in elderly patients
Dose adjustment in elderly patients is not required due to low systemic absorption.
Catarax is intended for long-term therapy. It is not recommended to interrupt treatment even in the event of a rapid clinical improvement.
Contact of the vial dropper with eyelashes, skin areas and other surfaces should be avoided to avoid contamination of the contents of the vial.
With the simultaneous use of several topical ophthalmic preparations, it is necessary to observe an interval between instillations of at least 10-15 minutes.
Very rare :
– eye irritation
With unknown frequency :
– eye pain
– dry eyes, increased tearing
– blurred vision
– eye hyperemia
– increased individual sensitivity to any component of the drug
– cataract requiring surgery and other eye diseases (for example, corneal ulcer)
Interactions with other medicinal products have not yet been established.
When using more than one topical ophthalmic drug, the interval between taking drugs should be at least 10-15 minutes.
For ophthalmic use.
Catarax contains thiomersal (a preservative), an organomercury compound that can cause a hypersensitivity reaction. In the event of hypersensitivity reactions, the use of the drug should be discontinued.
It also contains methyl parahydroxybenzoate and propyl parahydroxybenzoate as preservatives, which can cause an allergic reaction (possibly delayed).
Pregnancy and lactation
There is no sufficient experience in the use of Catarax during pregnancy and lactation (breastfeeding). Perhaps the use of Catarax in pregnant women and nursing mothers in the case when the expected therapeutic effect outweighs the potential risk of possible side effects in the fetus or child.
There is no sufficient experience in the use of Catarax in children. Perhaps the use of Catarax in children in the case when the expected therapeutic effect outweighs the potential risk of possible side effects.
It is recommended to remove contact lenses before instillation of the drug and put on no earlier than 15 minutes after instillation.
Features of the influence of the drug on the ability to drive vehicles or potentially dangerous mechanisms
As with other eye drops, temporary blurred vision or other visual disturbances may occur after instillation, which may affect the ability to drive vehicles or potentially dangerous machinery.
If blurred vision occurs after instillation, the patient should wait until vision is restored before driving vehicles or potentially dangerous machinery.
There were no cases of overdose.
Treatment: if an excess amount of the drug gets into the eye, rinse the eyes with plenty of warm water.
Store at a temperature not exceeding 25 0C in the original packaging.
Keep out of the reach of children!
Shelf life – 3 years.
The period of application after opening the vial is not more than 4 weeks.
Do not use the drug after the expiration date indicated on the package.